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Abstract
Background: In spite of a consistent protection against tuberculosis (TB) in children, Mycobacterium bovis Bacille Calmette-
Guerin (BCG) fails to provide adequate protection against the disease in adults as well as against reactivation of latent
infections or exogenous reinfections. It has been speculated that failure to generate adequate memory T cell response,
elicitation of inadequate immune response against latency-associated antigens and inability to impart long-term immunity
against M. tuberculosis infections are some of the key factors responsible for the limited efficiency of BCG in controlling TB.
Methods/Principal Findings: In this study, we evaluated the ability of a DNA vaccine expressing a-crystallin- a key latency
antigen of M. tuberculosis to boost the BCG induced immunity. ‘BCG prime – DNA boost’ regimen (B/D) confers robust
protection in guinea pigs along with a reduced pathology in comparison to BCG vaccination (1.37 log10 and 1.96 log10 fewer
bacilli in lungs and spleen, respectively; p,0.01). In addition, B/D regimen also confers enhanced protection in mice.
Further, we show that B/D immunization in mice results in a heightened frequency of PPD and antigen specific multi-
functional CD4 T cells (3+) simultaneously producing interferon (IFN)c, tumor necrosis factor (TNF)a and interleukin (IL)2.
Conclusions/Significance: These results clearly indicate the superiority of a-crystallin based B/D regimen over BCG. Our
study, also demonstrates that protection against TB is predictable by an increased frequency of 3+ Th1 cells with superior
effector functions. We anticipate that this study would significantly contribute towards the development of superior booster
vaccines for BCG vaccinated individuals. In addition, this regimen can also be expected to reduce the risk of developing
active TB due to reactivation of latent infection.
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Introduction
The success of Mycobacterium tuberculosis as a human pathogen
relies immensely on its ability to subvert the host immune
responses and persist in a dormant state. M. bovis Bacille Calmette-
Guerin (BCG) is currently the only tuberculosis (TB) vaccine
approved for human use. It has been used to vaccinate more than
4 billion individuals worldwide and still continues to be a part of
the childhood immunization program in most of the countries due
to its ability to impart effective protection against TB in children
[1]. However, the protective immunity generated by BCG wanes
off with age and its efficacy against the disease has been less than
satisfactory in adults and older individuals. Besides, the inability of
BCG to provide sterilizing immunity at the time of primary
infection leads to an enormous reservoir of asymptomatically
infected individuals worldwide (,2 billion). These latently infected
individuals have a persistent risk of developing clinical disease due
to endogenous reactivation if the immune system is compromised
due to several reasons such as HIV infection, malnourishment etc.
[2,3]. Latency-associated antigens are expressed by M. tuberculosis
while adapting to long-term persistence; however, BCG being an
attenuated strain does not persist long enough to express these
antigens. Thus, despite sharing a vast repertoire of antigens with
M. tuberculosis, BCG fails to elicit an efficient response against these
latency antigens [4,5,6]. Hence, the latency-associated antigens are
attractive targets for developing booster vaccines to enhance the
protective efficacy of BCG [6].
In the last five years, there has been a substantial progress in the
development of new TB vaccines and many of these have already
found their way into clinical trials or pre-clinical development [7].
However, most of these vaccines are based on the antigens that are
highly immunodominant and are recognized by the immune
system during the early stages of M. tuberculosis infection
[8,9,10,11]. There are very few vaccine studies employing antigens
expressed preferentially during adaptation of bacteria to long-term
persistence [6,12,13,14].
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Previously, we have reported the development of DNA vaccine
(DNAacr) expressing a-crystallin (acr, HspX, Rv2031c) [14] – a key
component of the dormancy regulon and one of the most
abundantly produced proteins during exposure of M. tuberculosis
to hypoxia, nutrient starvation as well as in the late stages of
infection [4,5,6]. We showed that this DNA vaccine induces Th1
response and protects guinea pigs against M. tuberculosis infection,
even though, it could not surpass the protective efficacy of BCG,
when employed alone in a prophylactic mode [14]. Recently, we
also showed that DNAacr efficiently boosts the immunity following
vaccination with a recombinant BCG vaccine over-expressing a-
crystallin [15]. However, as majority of global population
represents BCG vaccinated individuals, in this study, we have
evaluated the ability of a booster DNA vaccine expressing a-
crystallin to strengthen the immune responses and enhance and
prolong the protective efficiency of BCG. We show that a booster
vaccine targeting a latency antigen can substantially enhance the
protection imparted by BCG vaccine. We also show a distinct
association of multi-functional T cell responses with the vaccine-
induced protection.
Results
Enhanced protection by BCG prime-DNAacr boost
regimen
To evaluate the protective efficacy of ‘BCG prime-DNAacr
boost’ regimen (B/D), at 12 weeks after the primary immuniza-
tion, guinea pigs were infected with M. tuberculosis by aerosol route
and lung and spleen bacillary load were determined at 10 (Exp-I)
and 16 weeks (Exp-II) post-infection. At 10 weeks post-infection
(Fig. 1A), BCG vaccination resulted in a significantly reduced
bacillary load in the lungs and spleen when compared to the
unvaccinated animals (0. 94 log10 and 1.48 log10 fewer bacilli,
respectively, p,0.05). However, when DNAacr was employed as a
booster subsequent to BCG priming, the regimen conferred robust
protection as was evident from a remarkable reduction in the
bacillary load in the lungs and spleen (2.31 log10 and 3.44 log10
fewer bacilli, respectively, p,0.01), when compared to the
unvaccinated animals (Fig. 1A). Moreover, the magnitude of
protection by B/D regimen was especially noteworthy, as it
resulted in 1.37 log10 and 1.96 log10 fewer bacilli in lungs and
spleen, respectively in comparison to BCG vaccination (p,0.01),
(Fig. 1A).
In Exp- II, when the post-challenge period was prolonged to 16
weeks, one third of the saline treated animals (2/6) succumbed to
the disease. In the BCG vaccinated animals, although no mortality
was observed, the bacillary load in the lungs and spleens of these
animals was observed to be as much as in the case of unvaccinated
animals (surviving ones) indicating a considerable decline in the
protection conferred by BCG vaccination on extending the post-
challenge period to 16 weeks (Fig. 1B). However, B/D regimen
continued to provide a superior protection, as was evident from a
significantly reduced bacillary load in the lungs and spleen when
compared with the BCG vaccination (by 2.01 log10 and 1.47 log10,
p,0.05, respectively; p,0.05). The influence of boosting was
found to be antigen specific, since, boosting with vector DNA (B/
V) did not show any significant improvement over BCG
immunization (Fig. 1B).
Reduced pathology following B/D vaccination
On examining the influence of vaccination on pathological
damage in various organs of guinea pigs at 10 weeks post-infection,
we observed that unvaccinated animals exhibited severe pathology
in lungs, liver and spleen characterized by the presence of
numerous large and small sized tubercles (Fig. 2A). Vaccination of
animals with BCG and B/V resulted in significantly reduced gross
lesions in lungs, liver and spleen, when compared to the
unvaccinated animals. However, B/D vaccination imparted even
a more pronounced effect on pathology, such that, the majority of
animals vaccinated with this regimen exhibited only a minimal
pulmonary involvement along with markedly reduced gross lesions
in spleen when compared with BCG and B/V vaccinated animals
(Fig. 2A).
Histopathological analysis of lung and liver sections further
substantiated the gross pathological observations (Fig. 3A).
Unvaccinated animals exhibited wide spread granulomatous
inflammation with necrosis occupying 55% of the lung sections.
Vaccination with BCG, B/D as well as B/V regimens resulted in a
significantly reduced granulomatous inflammation in lungs
(p,0.01). However, in contrast to BCG and B/V vaccinated
animals which, showed the presence of granulomas covering 35%
and 30% of the lung sections, respectively, animals vaccinated
with B/D regimen exhibited well-preserved alveolar spaces with
only a few scattered areas of diffused infiltration in peribronchial
and perivascular areas (5%) (Fig. 3A). Similarly, in liver, the
unvaccinated animals exhibited effacement of a large proportion
of hepatic parenchyma by multi-focal necrotic granulomas
covering almost 35% of the liver sections. BCG and B/V
vaccinated animals exhibited minimal granulomatous inflamma-
Figure 1. Enhanced protection against M. tuberculosis challenge
by DNAacr boosting subsequent to BCG vaccination. For
evaluation of protective efficacy two guinea pig experiments were
performed. The figure depicts the bacillary load in the lungs and spleen
of vaccinated and saline treated guinea pigs at (A) 10 weeks (Exp-I,
n = 5) and (B) 16 weeks (Exp-II, n = 6) post-infection. Immunization with
B/D regimen resulted in a significantly lower bacillary load in lungs and
spleen, when compared to both BCG and saline groups. Log10 CFU
were measured and graphically represented by box plot, wherein
median values are denoted by horizontal line, the mean is represented
by ‘+’, inter quartile range by boxes, and the maximum and minimum
values by whiskers. The lower limit of detection was 1.0 log10 CFU/g of
tissue and animals with undetectable bacilli were allotted a CFU value
of 1.0 log10/g. B/D, BCG prime – DNAacr boost and B/V, BCG prime –
vector boost. *, p,0.05, **, p,0.01, ***, p,0.001, when compared to
the saline group or as indicated (One-way ANOVA).
doi:10.1371/journal.pone.0023360.g001
Boosting BCG Induced Immunity against TB
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23360
tion in liver (5%). However, architecture of hepatic lobules was
completely preserved in case of B/D vaccinated animals with no
evident sign of inflammation (Fig. 3A).
Similarly, at 16 weeks post-infection, as expected, lungs and
liver of unvaccinated animals exhibited extensive multi-focal
coalescing granulomas with prominent central coagulative necro-
sis. In comparison, BCG as well as B/V vaccinated animals
exhibited the presence of scattered areas of inflammation with
discrete as well as coalescing granulomas with small necrotic
centers in lungs (Fig. 2B and 3B). The liver of these animals,
however, exhibited a significantly reduced inflammation. In
contrast, B/D vaccinated animals exhibited only a negligible
inflammation in lungs. In addition, the liver of these animals was
also completely protected against pathological damage (Fig. 2B
and 3B).
In parallel, we also determined the antigen load in lung tissues
by in situ localization of Ag85 complex proteins, which serve as a
marker for live bacilli, dead bacilli, bacillary remnants as well as
secreted antigens [16]. We observed a strong positive correlation
between antigen load and bacillary count (r = 0.78, p,0.001).
Particularly, in concordance with the reduced bacillary load,
animals immunized with B/D regimen exhibited minimal antigen
load both at 10 and 16 weeks post-infection (Fig. 4). Commen-
surate with the extensive granulomatous inflammation, unvacci-
nated animals exhibited widespread fibrosis in and around the
pulmonary granulomas causing loss of alveolar structure (Quick
score, Q= 9 and 10.5, at 10 and 16 weeks, respectively) (Fig. 5).
BCG vaccinated animals exhibited a moderate collagen staining at
both the time points (Q= 4 and 7.5, at 10 and 16 weeks,
respectively). In contrast, animals vaccinated with B/D regimen
exhibited only a weak collagen staining in the lungs (Q= 2, at both
the time points), when compared with the BCG vaccinated
animals (p,0.05), (Fig. 5). The extent of collagen deposition also
showed a strong positive correlation with the bacillary load
(r = 0.879, p,0.001) and granulomatous inflammation (r = 0.876,
p,0.001).
Altogether, these observations suggest that vaccination with B/D
regimen, in addition to exerting an efficient control on bacillary
multiplication and imparting a markedly superior protection against
pathological damage and fibrosis, the regimen was also efficient in
meditating antigenic clearance from the site of infection.
Induction of multifunctional CD4 Th1 cell response by
B/D regimen confers enhanced protection in murine
model
The non-availability of immunological reagents, a persistent
caveat of guinea pig model, prohibited us from evaluating the T
cell effector functions and their association with the protection
imparted by various vaccination regimens. Hence, we evaluated
the protective efficacy of B/D regimen in murine model also along
with the associated immune responses.
At 4 weeks post M. tuberculosis infection, we observed a
significantly reduced bacillary load in the lungs and spleen of
BCG vaccinated animals when compared with the unvaccinated
animals (1.02 log10 and 0.48 log10 fewer bacilli in the lungs and
spleen, respectively), (Fig. 6A). A strikingly higher reduction in the
bacillary load was observed in case of animals vaccinated with B/
D regimen in comparison to the unvaccinated animals (by 1.69
log10, p,0.001 and 1.84 log10, p,0.01 fewer bacilli, respectively).
Even in comparison to the BCG vaccinated animals, the animals
vaccinated with B/D regimen exhibited a significantly reduced
bacillary load (by 0.67 log10 and 1.35 log10 fewer bacilli,
respectively, p,0.05), (Fig. 6A) indicating thereby that this
regimen provides a superior protection in comparison to BCG.
Further, we analysed the quality of T cell responses by
measuring the cytokine production on a per-cell basis by FACS
following a six-hour stimulation of splenocytes with PPD or a-
crystallin. T cells were purified, stained for CD4 T cell surface
marker along with IFNc, TNFa, and IL2 and were subjected to
FACS analysis. Quality of immune responses was defined on the
basis of expression of various combinations of these cytokines as
described by Seder et al [17]
Figure 2. Influence of vaccination on gross pathology following M. tuberculosis infection. The figure depicts representative photographs
and graphical depiction of gross scores of lung, liver and spleen of guinea pigs at (A) 10 weeks (n = 5) and (B) 16 weeks (n = 5) post-infection. Based on
the extent of involvement, number and size of tubercles, areas of inflammation and necrosis, gross pathological scores were graded from 1 to 4. Each
point represents score for an individual animal and the bar depicts median (6 inter-quartile range) for each group, *p,0.05 and **p,0.01, when
compared to the saline group (Mann-Whitney U test).
doi:10.1371/journal.pone.0023360.g002
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At 12 weeks post-primary immunization (at the time of infection),
although quantitatively, both BCG and B/D vaccinated animals
exhibited a comparable frequency of CD4 T cells (data not shown),
qualitatively, a marked functional heterogeneity was observed in
terms of their ability to produce IFNc, TNFa and IL2 (Fig. 6B).
Notably, B/D vaccinated animals exhibited a markedly higher
frequency of PPD specific 3+ (IFNc+TNFa+IL2+) and 2+ (TNFa+IL2+
and IFNc+IL2+) CD4 T cells when compared with the BCG
vaccinated animals (Fig. 6B). In addition, 3+ CD4 T cells specific to
PPD in B/D vaccinated animals also exhibited a markedly higher
iMFI for all the three cytokines, when compared with the BCG
vaccinated animals (Fig. 6C). In contrast, BCG vaccinated animals
exhibited a higher 1+ CD4 T cell response, with a characteristic
preponderance of IFNc+ and TNFa+ cells (Fig. 6B). Moreover, B/D
vaccination also boosted the multifunctional 3+ CD4 T cell response
specific to a-crystallin antigen (Fig. 6C). These observations indicate
that the enhanced protection by B/D regimen is associated with
augmentation of 3+ multifunctional CD4 T cell response.
Discussion
BCG has been the most widely used vaccine over the last several
decades with more than 4 billion Individuals vaccinated with it
worldwide. However, clinical trials and subsequent meta-analysis
revealed its general ineffectiveness against TB in adults [1]. As a
result, several laboratories all over the world have now directed
their focus towards the development of new candidate vaccines or
vaccination regimens that can improve upon the protection
conferred by BCG vaccine [7]. According to one of the proposed
mechanisms, as the individual reaches 10 to15 years of age, the
memory immunity generated by BCG declines resulting in a
gradual loss of efficacy of BCG [18]. Thus, introduction of a
booster vaccine based on a candidate antigen specifically
recognized by BCG induced immunity emerged as one of the
most successful approaches [18]. Among the various boosting
agents, vaccines of genetic nature such as DNA vaccines have
emerged as one of the most promising advancements in the field of
vaccine discovery. Immunization with DNA is known to direct the
immune system towards stronger and persistent cellular and
humoral immune responses [19]. This is especially advantageous
in the context of TB as the protective immunity against M.
tuberculosis is primarily dependent on the cell-mediated immune
responses [20]. Several of the DNA vaccine candidates, when used
in homologous prime boost regimen have exhibited a considerable
potential in mouse model of tuberculosis, such as, those expressing
Ag85A (mycolyl transferase) [21], ESAT-6 [14], PstS-1, PstS-3
Figure 3. Vaccination with B/D regimen reduces granulomatous inflammation in M. tuberculosis infected guinea pigs. The figure
depicts representative photomicrographs (46) of H&E stained lung and liver sections of guinea pigs at (A) 10 weeks (n = 5) and (B) 16 weeks (n = 5)
post-infection. H&E stained lung and liver sections were examined by light microscopy. Lungs: saline group exhibited multi-focal coalescing
granulomas with extensive necrosis; BCG group showed discrete granulomas with or without central necrosis and B/D group exhibited negligible and
diffused aggregates of inflammatory cells. Liver: saline group showed multiple granulomas, BCG vaccinated animals exhibited mild inflammation and
B/D vaccinated animals exhibited no evident signs of inflammation. Scale bar represents 2 mm. Pulmonary and hepatic consolidation were
graphically represented as % granuloma by box plot (notations are described in the legend of Fig. 1), *p,0.05 and **p,0.01, when compared to the
saline group (Mann-Whitney U test).
doi:10.1371/journal.pone.0023360.g003
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[22] and hsp65 [23], however, the protection conferred by these
vaccines was generally lower and rarely equal to BCG [24,25]. In
addition, they were found to be ineffective, when evaluated as a
standalone vaccine in a more stringent guinea pig model [21,26].
To date, a very few DNA vaccines have proved successful when
employed in a heterologous prime boost regimen with BCG, such
as DNA vaccines based on a fusion protein 72f and Hsp65 antigen
based DNA vaccine [27,28].
In this study, we show that a-crystallin (hspx, Rv2031c) based
DNA vaccine booster subsequent to BCG priming is highly
effective in improving the protection conferred by BCG. This
heterologous prime boost regimen provides a superior and
extended protection against M. tuberculosis infection in guinea pigs
as well as in mice. According to our previous findings, a-crystallin
based DNA vaccine, although, failed to surpass the protection
conferred by BCG vaccine, when used as a standalone vaccine
[14], it is was able to substantially improve the protection
conferred by a recombinant BCG vaccine over-expressing this
antigen [15]. Our current findings are thus, all the more important
as they signify that the meager immune responses generated by
BCG specific to a-crystallin can be substantially boosted by this
DNA vaccine resulting in enhanced and extended protection
superior to BCG.
Our observations in murine model further highlight the
association between the enhanced protection by B/D regimen
and the production of a heightened multi-functional (3+) CD4 T
cell responses along with production of overall larger quantities of
Figure 4. Influence of vaccination on the antigen load in
pulmonary granulomas post-infection. The representative photo-
micrographs (106) of 5 mm lung sections showing immuno-histochem-
ical staining (brown color) for Ag85 complex proteins in pulmonary
granulomas at (A) 10 weeks (Exp-I, n = 5) and (B) 16 weeks (Exp-II, n = 4)
post-infection. Unvaccinated animals exhibited extensive staining
surrounding and within the granulomatous areas; BCG vaccinated
animals exhibited a moderate antigen staining and B/D vaccinated
animals exhibited no evident sign of antigen staining in conjunction
with negligible granulomatous inflammation. Scale bar represents
1 mm. Extent (Q) of staining was measured [Quick score (Q) = intensity
(I) X area (A) of staining] and represented graphically as median (6 inter
quartile range). *, p,0.05 and **, p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0023360.g004
Figure 5. Influence of a-crystallin based prime boost vaccina-
tion on pulmonary fibrosis following M. tuberculosis infection.
The figure depicts representative photomicrographs (106) of Van
Gieson stained lung sections of guinea pigs euthanized at (A) 10 weeks
and (B) 16 weeks post-infection. Saline group exhibited extensive
fibrosis or collagen deposition (red color) in granulomatous lesions; BCG
group exhibited increased fibrosis with time and B/D group showed
complete disease resolution with no evident sign of fibrosis. Scale bar
represents 1 mm. Extent (Q) of pulmonary fibrosis was measured by
light microscopy [Q= Intensity (I) X area (A) of staining] and represented
graphically as median (6 inter quartile range). B/D, BCG prime – DNAacr
boost. **, p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0023360.g005
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IFNc, TNFa and IL2 by these T cells. Furthermore, an increased
frequency of 2+ CD4 T cells simultaneously producing TNFa and
IL2 in case of B/D regimen indicates the generation of a greater
central memory response in comparison to BCG. Though, more
extensive phenotyping of these 2+ T cells would have helped,
previous studies have proposed that while, the central memory T
cells produce IL2 alone or IL2 along with TNFa, the effector
memory T cells produce IFNc either alone or in combination with
IL2 and TNFa [17]. A lower degree of protection by BCG
vaccination despite the production of a comparable frequency of
CD4 T cells further illustrates that it is the functionality of T cells
and their ability to produce a broader repertoire of cytokines,
which plays a major role in the degree of protection conferred by a
vaccine. These observations are also in agreement with previous
studies, which have shown that T cells with multiple effector
functions, such as concomitant production of IFNc, TNFa and
IL2 are functionally superior to their counterparts producing only
a single cytokine [29]. In addition, induction of these multifunc-
tional T cells by vaccine regimens have also been shown to be a
potential correlate of protection against tuberculosis as well as
against other bacterial and viral diseases [30,31,32]. Although, the
CD4 Th1 cell responses in this study were analysed on pooled
samples and thus, need to be interpreted cautiously, enhanced
protection observed in case of B/D vaccination does indicate a
crucial role of these multifunctional CD4 Th1 cells in conferring
long-term protection against M. tuberculosis infection. Moreover,
caution should be exercised to extrapolate the mouse immunoge-
nicity data to guinea pigs due to inherently different responses of
the two species to M. tuberculosis infection until the immunological
reagents for guinea pigs become available and the involvement of
multifunctional T cells in mediating protection is formally
demonstrated in this species.
‘BCG prime-DNAacr boost’ regimen should be advantageous in
terms of several clinical applications. Firstly, in view of the large
population vaccinated with BCG, DNAacr boosting can be
expected to significantly enhance and prolong the protection
conferred by BCG vaccine. This prospect gains further strength
from an important finding, wherein Pathan et al. reported that the
effect of an efficient booster vaccine remains unaltered irrespective
of the time span between the primary BCG vaccination and
boosting; a comparable enhancement in immune responses was
observed, whether the booster was administered a few months or
Figure 6. B/D vaccination confers enhanced protection against M. tuberculosis challenge in mice and induces heightened
multifunctional CD4 T cell response. The figure depicts (A) the bacillary load in lungs and spleen of mice (n = 4) at 4 weeks post-infection and
(B–C) multifunctional T cell response at 12 weeks post-immunization. Mice experiment was performed once. (A) Log10 CFU is represented by box plot
(notations are described in the legend of Fig. 1). The lower limit of detection was 1.0 log10 CFU/g of tissue and animals with undetectable bacilli were
allotted a CFU value of 1.0 log10/g. *, p,0.05, **, p,0.01 and ***, p,0.001. (One-way ANOVA). (B–C) T lymphocytes were purified from PPD and a-
crystallin stimulated splenocytes (pooled from four mice per group) and stained for CD4 T cell surface marker along with intracellular cytokine
staining for IFNc, TNFa and IL2 followed by FACS analysis. (B) Represents frequency (%) of PPD and a-crystallin specific CD4 T cells expressing each of
the seven combinations of IFNc, TNFa and IL2. (C) Represents frequency of PPD and a-crystallin specific 3+ CD4 T cells along with MFI and iMFI for
IFNc, TNFa and IL2. B/D: BCG prime – DNAacr boost regimen.
doi:10.1371/journal.pone.0023360.g006
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many years after BCG vaccination [33]. Secondly, since, the
valuable attributes of BCG vaccination are preserved in this
strategy, DNAacr, as a booster vaccine would simplify the issues
related to the clinical testing of this regimen without hampering
the childhood immunization program. Thirdly, induction of an
efficient immune response by this regimen against a-crystallin can
also be speculated to reduce the occurrence of latent TB infection
by promoting clearance of the dormant bacilli. While, further
studies would be required to demonstrate these plausible
advantages, the importance of a-crystallin in protection against
TB is further substantiated by the observation in our laboratory,
wherein a-crystallin based DNA vaccine, when evaluated in
therapeutic mode as an adjunct to chemotherapy in a modified
Cornell model, was found to effectively promote bacillary
clearance, reduce the time of chemotherapy as well as confer a
significant protection against reactivation (unpublished observa-
tions). Moreover, a recent study by Aagaard et al has also
demonstrated that a multi-stage vaccine, which is based on
combination of early and latency-associated antigens not only
serves as an efficient booster to BCG vaccine conferring superior
protection in a prophylactic mode but also provides a significant
degree of protection against reactivation when employed alone as
an adjunct to chemotherapy [6]. Altogether, the success of a-
crystallin based DNA vaccine in this study would not only
contribute towards the development of efficient booster vaccines
for BCG but would also encourage the designing and evaluation of
TB vaccines for prophylactic as well as therapeutic purposes based
on latency antigens.
Materials and Methods
Ethics statement
Guinea pig experiments were reviewed and approved by the
Institutional Animal Ethics Committee of National JALMA
Institute for Leprosy & Other Mycobacterial Diseases, Agra,
India (Permit number: 101/1997/CPCSEA). Mice experiments
were reviewed and approved by the Institutional Animal Ethics
Committee of University of Delhi South Campus, New Delhi,
India (Permit number: 159/1999/CPCSEA). All animals were
routinely cared for according to the guidelines of CPCSEA
(Committee for the Purpose of Control and Supervision on
Experiments on Animals), India.
Bacterial strains, preparation of vaccines for
immunization and animals
M. bovis BCG (Danish strain, BCG laboratories, Chennai, India)
and M. tuberculosis (H37Rv strain, ATCC no. 25618, AIIMS, New
Delhi, India) were grown to mid-log phase in Middle Brook 7H9
media and stocks were prepared as described [16]. DNA vaccine,
pAK4-acry - expressing a-crystallin was prepared as described [14].
Outbred guinea pigs (Dunkin Hartley strain, female, 200–300 g)
were procured from Disease Free Small Animal House Facility,
HAU, India and maintained in the BSLIII facility at National
JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra,
India. Mice (Balb/c strain, female, 6–8 weeks) were procured from
National Centre for Laboratory Animal Science, National Institute of
Nutrition, Hyderabad, India and were maintained in the BSLIII
facility at University of Delhi South Campus, New Delhi, India.
Immunization of guinea pigs and evaluation of
protective efficacy against M. tuberculosis infection
For evaluation of protective efficacy, two guinea pig experi-
ments were performed. In each experiment, guinea pigs were
immunized with (i) 56105 CFU of BCG (in 100 ml of saline) by i.d.
route, (ii) BCG once, followed by a booster dose of DNAacr or
vector (100 mg in 100 ml of saline) by i.m. route at 6 weeks (B/D or
B/V) and (iii) 100 ml of saline by i.d. route (control group). Guinea
pigs were challenged 12 weeks after the primary immunization
with 50–100 bacilli of M. tuberculosis H37Rv via the respiratory
route in an aerosol chamber (Glasscol Inc.). Animals were
euthanized at 10 weeks post-infection in Exp-I and at 16 weeks
post-infection in Exp-II by intraperitoneal injection of Thiopen-
tone sodium (100 mg/kg body weight) (Neon Laboratories Ltd.).
After dissecting the animals, lungs, liver and spleen were scored for
pathological changes as described previously [16,34]. For
histopathological evaluation, all three lung lobes (right caudal,
middle and cranial) and a portion of left dorsal lobe of liver were
removed and fixed in 10% buffered formalin. Left caudal lung
lobe and cranial portion of spleen were aseptically removed for the
measurement of bacillary load. Lung and spleen bacillary load was
measured along with the evaluation of histopathological changes
as described [16]. The detection limit in case of both lung and
spleen CFU was 1.0 log10 CFU/g.
Evaluation of protective efficacy and immune responses
in mice
Protection studies in mice were carried out once similarly as
described for guinea pigs. To recapitulate, briefly, mice in groups
of 4 were immunized and infected following the same protocol as
used for guinea pigs. Immune responses were measured at 12
weeks post-immunization (at the time of infection). For evaluation
of protective efficacy, bacillary load in lungs and spleen was
determined at 4 weeks post-infection.
Cell Isolation, stimulation and flow cytometry for the
assessment of CD4 T cell responses
At 12 weeks post-primary immunization, T cell responses were
assessed by intracellular cytokine staining of CD4 T cells for IFNc,
TNFa, and IL2. Briefly, spleen cells were isolated as described
[35] and cultured in RPMI-GlutaMAXTM (containing 10% heat
inactivated FBS and 16antibiotic-antimycotic) (Invitrogen) in the
presence of PPD (20 mg/ml) (Statens Serum Institut) or purified a-
crystallin (40 mg/ml) for 2 hr at 37uC. Thereafter, GolgiStop was
added and cells were incubated for an additional 4 hr before
intracellular cytokine staining.
Following stimulation, cells were purified by using BD IMagTM
Mouse T Lymphocyte Enrichment Kit. Briefly, a cocktail of
biotinylated antibodies was added to the cells that simultaneously
bind erythrocytes and leukocytes but not T lymphocytes. The cells
were then washed to remove excess antibodies followed by the
addition of BD IMagTM Streptavidin. Unlabelled T lymphocytes
were then enriched by negative selection by placing them within
the magnetic field of the BD IMagnetTM. Cells were washed and
incubated with BD Fc BlockTM (CD16/CD32 mAb to block Fc
binding). Subsequently, the cells were stained for cell surface
marker, CD4 (FITC) along with intracellular cytokines, IFNc
(RPE), TNFa (PerCPCy5.5) and IL2 (APC) by using the BD
Cytofix/Cytoperm kit. Cells were washed twice with Cytoperm
and finally resuspended in sheath fluid. Cells (50,000–100,000)
were acquired by using a FACS Calibur flow-cytometer (by using
Cell Quest Pro software) and analyzed by using FlowJo software
(Tree Star). Cell frequency, median fluorescence intensity (MFI)
and integrated MFI (iMFI=% frequency X MFI) for different
cytokines were calculated. For cell stimulation and FACS analysis,
cells pooled from all 4 mice from a group were used. All the
reagents for cell isolation and antibodies employed in FACS
analysis were obtained from BD Pharmingen.
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Immunohistochemistry and image analysis
For in situ localization of M. tuberculosis antigens in the sections of
guinea pig lungs, immunohistochemical (IHC) staining was carried
out and analysed for area and intensity of staining as described
earlier [16].
Statistical analysis
For comparison of the CFU one-way ANOVA was carried out
followed by Tukey test. Non-parametric Kruskal-Wallis test,
followed by Mann-Whitney U test were employed for comparison
of the quick score (Q) for IHC, gross pathological score and
granuloma % across different groups. Correlation between
different parameters was analysed by Spearman Rank Correlation
test. Differences were considered significant, when p,0.05. For
statistical analysis SPSS (Version. 10.0, SPSS Inc.) and Prism 5
(Version 5.01; GraphPad Software Inc.) were employed.
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